Rystiggo MG denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for rystiggo mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied Rystiggo (rozanolixizumab-noli) as Duplicate Therapy — and Why You Can Appeal

Cigna may deny Rystiggo for generalized myasthenia gravis (gMG) on a "duplicate therapy" basis when a patient is already receiving or has recently received another FcRn inhibitor, complement inhibitor, or other biologic approved for gMG. The insurer's position is that two agents targeting overlapping pathophysiological pathways cannot both be medically necessary simultaneously. However, this rationale is frequently overstated: combination or sequential use of mechanistically distinct agents in gMG is an area of active clinical practice, and the "duplicate" label may not accurately reflect the clinical scenario when drugs act via different mechanisms or when the concurrent therapy is being tapered.

## Your Appeal Rights

Under ACA Section 2719, non-grandfathered plans must provide independent external review after internal appeals. ERISA Section 503 requires a full-and-fair review with a written, specific explanation of any continued denial. If your myasthenia gravis is in an acute exacerbation or crisis, you may request expedited appeal processing, which operates on a compressed timeline. The standard external review window is generally available for roughly four months after internal remedies are exhausted.

## The Appeal Process and Timeline

1. Request the denial letter — it must identify the specific drug or therapy considered duplicative. 2. File a first-level internal appeal within the timeframe stated (often 180 days), attaching clinical documentation. 3. If denied, escalate to external review; external reviewers are not bound by Cigna's internal formulary or policy interpretations. 4. Request a peer-to-peer review between your neurologist and Cigna's medical reviewer — mechanistic distinctions in gMG biology are often persuasive at this stage.

## Documentation to Gather

• Diagnosis confirmation: records establishing gMG diagnosis, antibody status (AChR, MuSK, or seronegative), and disease severity classification.
• Mechanism distinction letter: a letter from the treating neurologist explaining the mechanistic difference between Rystiggo and any other concurrent or recent therapy, and why both are clinically necessary (or why the other is being discontinued).
• Treatment history and outcomes: documentation of all prior gMG therapies — with dates, doses, and clinical response — to establish treatment-refractory status and the rationale for the current regimen.
• Clinical severity documentation: objective measures of gMG severity from the chart (functional scales, respiratory status, crisis history) demonstrating the seriousness of disease activity.
• Taper plan if applicable: if the "duplicate" agent is being tapered, provide the treating plan and timeline to show concurrent use is transitional, not indefinite.

## Criteria-Mapping Structure

Obtain Cigna's published coverage policy for Rystiggo or biologics in gMG and identify the specific provision defining "duplicate therapy." For each criterion, provide the chart fact or physician statement that addresses it. If Cigna's own policy does not prohibit combination use or transitional overlap, quote the policy language directly in the appeal letter to show the denial exceeds the policy's stated scope.